Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
After obtaining favorable results in the investigator-initiated Phase III trial JETALS, and following consultation with Tokushima University, Eisai submitted a new drug application for the treatment of ALS in Japan in January 2024, leading to its approval in September, 2024 and leading to the launch today
Liver: Anatomy susceptible to injury
However, all applications should be considered experimental pending additional clinical research
The latter are subject to a number of homeostatic mechanisms
Researchers find it a fascinating topic due to its numerous crucial roles in human physiology [5]
Category 3 These substances did not have enough supporting information submitted for review
US$ 20.33
US$ 21.70
US$ 27.90
